| Linsitinib studied in …STUDIED_INderived20 of 20show fewer |
|---|
| → studied in | NCT01186861Phase 2 · completed Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy · 20 trials list this drug (0 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01221077Phase 2 · completed Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene · 20 trials list this drug (0 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00514007Phase 1 · completed Study of Continuous OSI-906 Dosing · 20 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00514306Phase 1 · completed Study of Intermittent OSI-906 Dosing · 20 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00739453Phase 1 · completed A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®) · 20 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00889382Phase 1/Phase 2 · completed A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) · 20 trials list this drug (0 active) | — | — | Solid Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00924989Phase 3 · completed A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma · 20 trials list this drug (0 active) | — | — | Adrenal Cortical Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01101906Phase 2 · terminated A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC · 20 trials list this drug (0 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02057380Phase 2 · completed A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial · 20 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01529684Phase 1 · completed A Study to Look at How a Single Oral Dose of 14C-OSI-906 is Absorbed, Broken Down and Eliminated in the Body · 20 trials list this drug (0 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01154335Phase 1 · completed Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer · 20 trials list this drug (0 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02546544Phase 2 · completed Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma · 20 trials list this drug (0 active) | — | — | Ewing Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01560260Phase 2 · completed Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors · 20 trials list this drug (0 active) | — | — | Chondrosarcoma,Gastrointestinal Stromal Tumor,Paraganglioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01533181Phase 2 · completed Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer · 20 trials list this drug (0 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01533246Phase 2 · completed Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer · 20 trials list this drug (0 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01465815Phase 1/Phase 2 · withdrawn Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) · 20 trials list this drug (0 active) | — | — | Malignant Skin Neoplasm,Skin Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01016860Phase 1 · terminated OSI-906 and Irinotecan in Patients With Advanced Cancer · 20 trials list this drug (0 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01013506Phase 2 · withdrawn Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer · 20 trials list this drug (0 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427205Phase 2 · withdrawn Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) · 20 trials list this drug (0 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01205685Phase 2 · terminated Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer · 20 trials list this drug (0 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |